Blue Cohosh

What is Blue Cohosh?

Blue cohosh is the dried root and rhizome of Caulophyllum thalictroides (L.) Michx., a spring woodland perennial in the barberry family, Berberidaceae, growing 1 to 2 feet tall from New Brunswick south to South Carolina and west to Arkansas and Manitoba. It is one of three species in its genus, alongside C. giganteum in eastern North America and C. robustum in northeast Asia. It is not black cohosh, which is Actaea racemosa, formerly Cimicifuga racemosa, in a different family, the Ranunculaceae. The two share a borrowed Algonquian word and nothing else, and everything below applies to blue cohosh alone. King's American Dispensatory of 1898 printed "(U. S. P.)" beside the entry, because blue cohosh was then an official drug of the United States Pharmacopeia.

Common Names

• Blue cohosh

• Papoose root

• Blueberry root

• Yellow ginseng

• Caulophyllum, the homeopathic and Eclectic name

Primary Active Compounds

• N-methylcytisine, also called caulophylline, a quinolizidine alkaloid and nicotinic acetylcholine receptor agonist structurally related to cytisine and to nicotine

• Anagyrine, the quinolizidine alkaloid responsible for crooked calf disease in cattle

• Baptifoline, lupanine, sparteine, alpha-isolupanine and 5,6-dehydro-alpha-isolupanine, additional quinolizidines, plus the aporphine alkaloid magnoflorine

• Taspine, highly embryotoxic in rat embryo culture, and thalictroidine, first described from this plant by Kennelly and colleagues in 1999

• Triterpene saponins on hederagenin, caulophyllogenin and echinocystic acid aglycones, including caulosides A, C, D, G and H, leonticin D and saponin PE, historically lumped under the names caulosaponin and caulophyllosaponin

Key Note

Blue cohosh is a medicinal root, not a nutrient. Its historical purpose was narrow: taken in the final weeks of pregnancy as what the Eclectic physicians called a partus praeparator, a use adopted from Native American practice and carried into Eclectic medicine and then into modern American midwifery. That single use accounts for essentially all of its documented human harm, and every one of those harms was measured in a baby rather than in the woman who took the dose.

This is one of the few plants on a supplement shelf where the safety data is unambiguous, the mechanism is specific, and the evidence of benefit is functionally zero.

Primary Functions & Benefits

There is no therapeutic function for blue cohosh supported by controlled human evidence. What follows is the claimed function set and what stands behind each claim.

Uterine stimulation and labor induction

This is the reason blue cohosh exists commercially. The traditional claim is that it ripens the cervix, coordinates contractions and shortens labor. The pharmacological basis is the saponin fraction, characterized by Ferguson and Edwards in the Journal of the American Pharmaceutical Association in 1954, volume 43, pages 16 to 21. The NIH LactMed monograph, last revised December 15, 2024, states plainly that caulosaponin "constricts coronary vessels and may have oxytocic activity." No randomized trial of crude blue cohosh for labor induction has ever been run in humans.

Menstrual regulation, antirheumatic and nervine use

Menstrual regulation is traditional Eclectic use with no clinical trial behind it; the Natural Medicines monograph rates this and every other listed use as insufficient evidence to rate. The antirheumatic work is on a different species: Wang and colleagues reported in Evidence-Based Complementary and Alternative Medicine in 2017, article 8134321, that a Caulophyllum robustum extract reduced arthritis index, IL-1, IL-6, TNF-alpha and PGE2 in collagen-induced arthritis in DBA/1J mice. Blue cohosh also appears in products marketed for nerves, mood, memory and hearing, with no human evidence for any of them.

Forms & Standardization

There is no standardized blue cohosh. No marker compound is certified, no extract ratio dominates, and the analytical literature shows the products differ from each other by orders of magnitude.

Powdered root, loose and encapsulated

450 mg is the standard capsule. TerraVita directs one capsule three times daily, or 1,350 mg of root per day; Nature's Sunshine directs one twice daily, or 900 mg. Same plant, same capsule weight, a 50 percent difference in labeled daily dose. TerraVita also sells a 4:1 dry extract as loose powder and as a 450 mg capsule, each notionally representing 1.8 g of starting root.

Hydroalcoholic tinctures, 1:3 to 1:8

Herb Pharm sells a certified organic 1:5 in cane alcohol and water, 0.7 mL delivering 140 mg of dried rhizome equivalent, 2 to 4 times daily, or 280 to 560 mg per day. Village Vitality lists a 1:3 at 333 mg of herb equivalent per mL. Hawaii Pharm's 1:3 lists 330 mg of dry plant per mL at 20 to 30 drops up to four times daily, roughly 1,300 mg. Pure Herbs lists a 1:8 delivering 1,909 mg of herb equivalent in a single 2 mL daily serving at 28 to 38 percent alcohol.

Concentrated fluid extract and glycerites

Nature's Answer lists 1,000 mg of root and rhizome extract per mL, 0.5 to 1 mL twice daily, up to 2,000 mg per day, the top of the market. Across single-herb products the labeled daily dose spans roughly seven-fold before any variation in the root itself. TerraVita sells an alcohol-free glycerite in chocolate, vanilla, strawberry and mint.

Homeopathic Caulophyllum

Boiron and others sell Caulophyllum thalictroides at 4CH through 15CH. At 5CH and above there is no meaningful plant material present. These are the only preparations that have been through randomized trials, and they are chemically unrelated to the crude root discussed everywhere else here.

What the analysis shows about all of it

Ganzera and colleagues at the University of Mississippi applied an HPLC method with evaporative light scattering detection to commercial products in Phytochemical Analysis in 2003, volume 14, pages 1 to 7, and found a greater than 100-fold difference in daily saponin intake between them. Satchithanandam and colleagues at the FDA's Center for Food Safety and Applied Nutrition published a broader survey in the Journal of AOAC International in 2008, volume 91, pages 21 to 32, calculating maximum daily intakes from label directions: alkaloids from under 1 mg to 75 mg per day, saponins from about 9 mg to 420 mg per day. A 75-fold spread in alkaloid dose and a 47-fold spread in saponin dose, from products a buyer would consider interchangeable.

Rader and Pawar, also at FDA, reviewed the quantitative literature in Analytical and Bioanalytical Chemistry in 2013, volume 405, pages 4409 to 4417. N-methylcytisine, which they call a potent toxicant, was found in every blue cohosh supplement analyzed; anagyrine, the teratogenic alkaloid, in some and not others. Woldemariam and colleagues at King's College London had earlier measured individual alkaloids in the roots at 0.02 to 1.1 percent by weight in the Journal of Pharmaceutical and Biomedical Analysis, 1997, volume 15, pages 839 to 843, a 55-fold range inside the raw material before any manufacturer touches it.

Food Sources

Blue cohosh is not a food and has no food sources. The plant produces blue, berry-like seeds about a third of an inch across in late summer, which look edible and are not. North Carolina Extension lists both the roots and the seeds as poison parts, with alkaloids and saponins as the toxic principle and nicotine-like symptoms at higher exposure, and raw seed poisoning in children appears in the older toxicology literature. Roasting the seeds as a coffee substitute is a documented historical practice, apparently because roasting reduced the alkaloid content enough to tolerate, but that is a footnote and not a recommendation.

There is no dietary intake of blue cohosh in any population and no food fortified with it. Every gram consumed comes from a deliberate purchase.

Who Should Take Blue Cohosh

Nobody, and the reason is short. There is not a single randomized controlled trial of crude blue cohosh for any indication in any population. Every claimed benefit rests on nineteenth century clinical impression, in vitro tissue work or rodent studies. The Natural Medicines database rates blue cohosh "likely unsafe" for adults taken orally and lists insufficient evidence to rate effectiveness for every indication including labor induction. Dugoua and colleagues at the Hospital for Sick Children in Toronto reviewed the whole safety record in the Canadian Journal of Clinical Pharmacology in 2008, volume 15, pages e66 to e73, and concluded it should not be available to the public as an over-the-counter product at all.

The one thing worth noting here is what the trade association says. The American Herbal Products Association's Botanical Safety Handbook assigns blue cohosh safety class 2b, "not to be used during pregnancy," and then carves out an exception for use as a parturient near term under the supervision of a qualified practitioner. That exception is precisely the use that produced every neonatal case in the literature.

Who Should AVOID or Use Caution

Contraindications

• Pregnancy at any stage. The teratogenic alkaloid data, the neonatal case reports and the AHPA class 2b designation all point the same direction.

• Attempted self-managed abortion. Rao and Hoffman reported a 21 year old woman in Veterinary and Human Toxicology in August 2002, volume 44, pages 221 to 222, who developed a nicotinic toxidrome after taking blue cohosh tincture to induce abortion.

• Breastfeeding. LactMed states that no data exist on safety in nursing mothers or infants and that most sources recommend strongly against use during breastfeeding.

• Known cardiovascular disease, given the coronary vasoconstrictor signal and myocardial toxicity in animal work.

• Children. The seeds are toxic and the alkaloid profile is nicotinic.

Use Caution

• Anyone taking a drug metabolized by CYP3A4, CYP2C19, CYP2D6 or CYP1A2. Madgula and colleagues reported in Planta Medica in March 2009, volume 75, pages 329 to 332, that the alkaloid fraction inhibited all four by more than 80 percent at 100 micrograms per mL, with IC50 values of 2 to 20 micrograms per mL.

• Anyone on nicotine replacement, varenicline or cytisine, since N-methylcytisine acts at the same receptor family.

• Anyone with hypertension, since elevated blood pressure is reported at higher intakes.

• Anyone with diabetes on glucose-lowering medication, given reported effects on blood sugar.

• People handling the raw plant, which causes contact dermatitis.

Critical Safety Point

The most dangerous property of blue cohosh is not its toxicity but that the toxicity is silent in the person who chooses to take it. A woman at 36 weeks taking a labor-prep tincture will in almost all cases feel entirely normal. There is no warning sign, no nausea threshold, no signal that tells her to stop. The first evidence that anything went wrong arrives in the delivery room, in a different patient, at a point where nothing can be undone.

Recommended Dosages

There is no evidence-based dose for blue cohosh, because no trial has established one. The numbers below are what is printed on labels and in historical texts, presented so a reader can see the spread, not as guidance.

Dried root and extract ranges

Historical Eclectic dosing ran 0.3 to 3 g per day, a 10-fold band with nothing separating one end from the other. Modern secondary sources give 0.5 to 3 mL per day of a 1:2 liquid extract, or 300 to 1,000 mg per day of whole herb. King's 1898 gave the infusion at 1 to 3 ounces every 3 or 4 hours, specific caulophyllum at 3 to 10 drops, caulophyllin at 2 to 4 grains and Lloyd's Leontin at 5 to 15 drops. Current label ranges are in section 4.

Duration

Labor-prep products are directed for use across the last 5 weeks of pregnancy, which means 35 consecutive days of a nicotinic alkaloid and an oxytocic saponin crossing a placenta at a stage where no exposure study exists. Nothing establishes a safe duration, because nothing establishes a safe dose.

Timing & Administration

Label directions place blue cohosh with or between meals, two to four times daily, in water or juice. The tinctures run 28 to 38 percent alcohol by volume, and glycerite versions exist for that reason, producing the odd result that a manufacturer will remove the ethanol on safety grounds while leaving the nicotinic alkaloid in place.

There is no pharmacokinetic study of blue cohosh alkaloids or saponins in humans. Absorption, half-life, protein binding and placental transfer are all unmeasured. Briggs's Drugs in Pregnancy and Lactation states that no studies describing placental crossing of any constituent have been located, while noting that alkaloid passage is presumed probable from animal evidence and the neonatal cases themselves. The most important pharmacokinetic parameter for this plant, whether it reaches the fetus, has been established only by the harm it caused.

Timeline of Effects

Acute effects, within hours

In the Rao and Hoffman case the adult nicotinic toxidrome appeared within hours of tincture ingestion and resolved over 24 hours. The McFarlin survey found that 21 percent of certified nurse-midwives using herbal labor stimulants reported complications, specifically precipitous labor, tetanic uterine contractions, nausea and vomiting. Tetanic contraction is not a slow effect.

Claimed partus praeparator effect, 2 to 5 weeks

King's American Dispensatory in 1898 described the practice as taking a decoction "for 2 or 3 weeks previous to labor." The current commercial protocol runs five weeks. No trial has tested whether either changes any labor outcome.

Neonatal harm, immediate to 26 hours after birth

Two of the three published infants were symptomatic at delivery. The third seized at 26 hours. Details are in section 12. This is the only timeline here with patient-level published data behind it, and it is a timeline of injury rather than benefit.

What counts as a fair trial

Nothing, because there is no outcome to measure and no design that could ethically test the primary use. That is a permanent feature of this ingredient rather than a gap waiting to be filled.

Benefits of Taking Blue Cohosh

There are no benefits of blue cohosh established by controlled human evidence. What exists is tradition and a small preclinical literature.

What tradition claims

Native American use as a labor preparative, documented in an 1847 medical text and by King's American Dispensatory in 1898, was adopted by Eclectic physicians who reported that it "relieves false pains and coordinates muscular contractions" and gave "tone and vigor to all the parts engaged in the accouchement." Whatever they observed, they observed without controls, without blinding, and without knowing their preparation contained a nicotinic agonist.

What the trials show

Two randomized trials totaling 133 women exist, both of homeopathic caulophyllum rather than the herb, pooled by Smith in the Cochrane Database of Systematic Reviews, CD003399, updated in 2003. Both were placebo controlled, double blind and low quality, and neither found a difference in any outcome. Dante and colleagues, reviewing herbal therapies in pregnancy in Current Opinion in Obstetrics and Gynecology in April 2014, volume 26, pages 83 to 91, screened 671 articles and found 15 randomized and 16 nonrandomized trials across all pregnancy herbs combined. They named ginger as the only remedy with consistent supporting data, and blue cohosh and evening primrose oil as the two associated with severe adverse events.

Potential Negatives & Side Effects

In the person taking it

• Nicotinic toxidrome: tachycardia, diaphoresis, abdominal pain, vomiting, muscle weakness and fasciculations, documented in the Rao and Hoffman 2002 case.

• Nausea, vomiting, diarrhea and stomach cramps.

• Elevated blood pressure and elevated blood sugar at larger intakes, and chest pain.

• Contact dermatitis from handling the plant.

• Tetanic uterine contractions and precipitous labor, reported by 21 percent of the midwives in the McFarlin survey who used herbal labor stimulants.

• Drug interference through CYP inhibition, covered in section 17.

In the fetus and newborn, which is the real risk profile

Three published cases, in full.

Gunn and Wright, New Zealand Medical Journal, October 25, 1996, volume 109, issue 1032, pages 410 to 411. The mother took both black and blue cohosh to induce labor. The female infant was not breathing at birth, with Apgar scores of 1, 4 and 5, and required mechanical ventilation. She developed seizures, acute tubular necrosis and hypoxic injury to the basal ganglia, and survived with permanent central nervous system damage. Baillie and Rasmussen replied for the herbal position in the same journal on January 24, 1997, volume 110, issue 1036, pages 20 to 21.

Jones and Lawson, Journal of Pediatrics, March 1998, volume 132, part 1, pages 550 to 552, from the University of Washington School of Medicine. The mother took blue cohosh tablets to promote uterine contractions, reportedly three times daily for five weeks rather than the once daily she had been directed to take. The male infant presented at birth with acute myocardial infarction, profound congestive heart failure, cardiomegaly, pulmonary edema and shock, with other causes of infarction carefully excluded. He was critically ill for weeks and discharged after 31 days. At age 2 he still had cardiomegaly and reduced left ventricular function and remained on digoxin. Wright commented in the same journal in March 1999, volume 134, pages 384 to 385.

Finkel and Zarlengo, New England Journal of Medicine, July 15, 2004, volume 351, pages 302 to 303. A healthy 24 year old at 40 weeks drank blue cohosh tea to stimulate labor. The female infant weighed 3,860 g. Focal motor seizures of the right arm began at 26 hours of age, computed tomography showed an evolving infarct in the left middle cerebral artery distribution, and the seizures were controlled with phenobarbital and phenytoin. This case carries an honest confounder: urine and meconium were positive for the cocaine metabolite benzoylecgonine, and so were two commercial blue cohosh products that were tested. Whether that reflects contamination, cross-reactivity or separate exposure was never resolved, and two sets of correspondents said so in the same journal on November 18, 2004, volume 351, pages 2239 to 2241. The stroke is real either way; the attribution is less certain than in the other two cases.

The asymmetry is the point. The mother's side of this section is uncomfortable. The infant's side is catastrophic, and both come from the same swallow.

Deficiency Symptoms

Blue cohosh is not an essential nutrient and there is no deficiency state. No human process requires N-methylcytisine, caulosaponin, taspine or magnoflorine. There is no reference intake, no biomarker, no depletion syndrome and no population ever shown to have too little.

What blue cohosh addresses

Nothing that can be measured. The traditional targets, slow labor and menstrual irregularity, have defined clinical pathways that do not involve this plant. Oxytocin, misoprostol, dinoprostone and transcervical balloon catheters have dose-response data, safety monitoring and randomized evidence. Blue cohosh has three published cases of neonatal injury and no efficacy trial.

Bottom line

Nobody has ever been blue cohosh deficient. The question here is not whether a buyer is getting enough of it. It is why it is still sold in chocolate flavor.

Toxicity Symptoms

At high intake

Nicotinic poisoning is the acute picture: tachycardia, sweating, abdominal pain, vomiting, muscle fasciculation and weakness. Schep, Slaughter and Beasley placed Caulophyllum in their review of nicotinic plant poisoning in Clinical Toxicology in September 2009, volume 47, pages 771 to 781. North Carolina Extension classifies poison severity as low for incidental ingestion and notes high blood pressure and nicotine-like symptoms if eaten in excess.

Datta and colleagues at the University of Mississippi added a mechanism in the Journal of Natural Products in January 2014, volume 77, pages 111 to 117. They screened extracts from 352 authenticated plant samples for the ability to disrupt cellular respiration, and blue cohosh methanol extract came out positive. Three saponins, cauloside A, saponin PE and cauloside C, produced concentration and time-dependent mitochondrial toxicity: respiration rate spiked and then collapsed within minutes through disruption of mitochondrial membrane integrity. The authors framed this as a plausible link to the idiosyncratic organ damage reported with this plant.

Signs to reduce or stop

Racing heart, sweating, muscle twitching, unexplained weakness, chest discomfort, vomiting or abdominal pain after taking blue cohosh warrants stopping and calling a poison center. In a pregnant woman there is no threshold at which continuing is defensible, because the toxicity that matters most produces no symptoms in her at all.

General note

The usual reassurance for botanical supplements, that a person would have to consume an implausible quantity to reach a toxic dose, does not hold. The exposure in the Journal of Pediatrics case was a labor-prep tablet regimen, and the outcome was myocardial infarction in a newborn.

How Blue Cohosh Works

Two chemical classes drive everything blue cohosh does, and they work by different routes.

The alkaloids act at nicotinic acetylcholine receptors

N-methylcytisine is a quinolizidine alkaloid and a close structural relative of cytisine, the compound that gave rise to varenicline. Cytisinoids as a class prefer heteromeric alpha4beta2 nicotinic receptors over the homomeric alpha7 subtype, as Abin-Carriquiry and colleagues showed by docking cytisine and N-methylcytisine into an acetylcholine binding protein structure in Bioorganic and Medicinal Chemistry Letters in June 2010, volume 20, pages 3683 to 3687. Nicotinic agonism at ganglionic and neuromuscular sites explains the adult toxidrome directly, and it also explains the vascular signal: reduced coronary flow has been observed in rat heart preparations infused with N-methylcytisine, and a vasoconstrictive effect in hog and cattle carotid artery preparations exposed to it.

The saponins act on smooth muscle and on mitochondria

The triterpene saponins are the fraction credited with uterine stimulation, and the LactMed monograph attributes coronary vessel constriction and possible oxytocic activity to caulosaponin specifically. The Datta work adds a second saponin mechanism that is not receptor-mediated at all: caulosides A and C and saponin PE physically disrupt mitochondrial membrane integrity, collapsing respiration within minutes. Saponins are surfactants, and that is a surfactant effect.

Why the neonatal events are pharmacologically coherent

Put the two together and the case reports stop looking like coincidence. A nicotinic agonist that reduces coronary flow, a saponin class that constricts coronary vessels and poisons mitochondria, and a uterine stimulant that increases contraction frequency and therefore reduces placental perfusion between contractions, converge on exactly what was reported: neonatal myocardial infarction, arterial ischemic stroke and multi-organ hypoxic injury. The 1996 New Zealand authors proposed reduced placental perfusion from increased uterine activity as the mechanism in their case. The fetal myocardium is unusually vulnerable to this combination, having minimal coronary reserve and depending entirely on maternal-placental oxygen delivery.

The teratogenic route is separate

Kennelly and colleagues, working with the FDA's Center for Food Safety and Applied Nutrition, tested isolated blue cohosh alkaloids in an in vitro rat embryo culture and published in the Journal of Natural Products in October 1999, volume 62, pages 1385 to 1389. N-methylcytisine was teratogenic in the assay. Taspine was highly embryotoxic but not teratogenic. Thalictroidine, anagyrine and alpha-isolupanine were not teratogenic at the concentrations tested. Anagyrine is separately established as the cause of crooked calf disease in cattle grazing lupines, and it is present in some blue cohosh supplements and absent from others.

Synergistic Supplements

Synergy is a concept for ingredients with an established benefit to amplify, so this section does not apply. The combinations sold commercially compound the problem instead.

Black cohosh is the most common pairing and the most confusing. Actaea racemosa is a different plant in a different family with a different mechanism and a different safety file, including a hepatotoxicity signal blue cohosh does not have. The 1996 New Zealand mother took both, which is exactly why that outcome cannot be attributed to either ingredient alone. The wider labor-prep stack is red raspberry leaf, evening primrose oil, castor oil, false unicorn, partridge berry and blessed thistle: in the McFarlin survey, of the certified nurse-midwives using herbal labor stimulants, 93 percent used castor oil, 63 percent red raspberry leaf, 64 percent blue cohosh, 60 percent evening primrose oil and 45 percent black cohosh.

Interactions & What NOT to Take

Nicotine, varenicline and cytisine

Direct pharmacodynamic overlap. N-methylcytisine is an agonist at the same receptor family targeted by nicotine replacement products and by both approved cytisinoid smoking cessation drugs. Additive nicotinic effects are predictable.

Drugs metabolized by CYP3A4, 2C19, 2D6 and 1A2

Madgula and colleagues found the alkaloid fraction inhibited all four enzymes by more than 80 percent at 100 micrograms per mL, IC50 2 to 20 micrograms per mL. Individually, caulophyllumine B, O-acetylbaptifolin, anagyrine and lupanine gave IC50 values of 2.5 to 50 micromolar. N-methylcytisine itself was weak, inhibiting only CYP3A4 by 32 percent at 100 micromolar, and caulosides C and D inhibited CYP3A4 by 43 and 35 percent at the same concentration. An equimolar alkaloid mixture inhibited more strongly than any single alkaloid, which argues against treating the whole extract as a sum of its tested parts.

Antihypertensives and antidiabetic medications

Both are reported to lose effectiveness alongside blue cohosh, consistent with its pressor effect and its reported increase in blood glucose.

Oxytocin, misoprostol and dinoprostone

Not a documented pharmacokinetic interaction but a serious practical one. In the McFarlin survey, 75 percent of the midwives using herbal labor stimulants used them first or instead of pitocin, and 78 percent prescribed them directly while only 22 percent had them in written practice protocols. An uncontrolled uterine stimulant of unknown potency stacked with or preceding a titratable one is a recipe for tetanic contraction, which is what 21 percent of those midwives reported.

Quality, Testing & Adulteration

This is where blue cohosh looks worst, because the analytical work has been done and the answers are documented.

The toxic constituent is universal, the teratogenic one is a lottery

Rader and Pawar found N-methylcytisine in every dietary supplement analyzed and anagyrine in some products and not others. No label distinguishes them, and no product on the market discloses either compound. That sits on top of the 100-fold saponin spread and the 75-fold alkaloid spread described in section 4.

No certification program covers it

There is no USP Verified blue cohosh product, no NSF certification, and no published ConsumerLab test of the category. Nothing on the market carries an independent identity or potency mark. Herb Pharm publishes a 1:5 dry herb to menstruum ratio and a certified organic sourcing claim, which addresses agriculture but not alkaloid content.

The certificate of analysis, and the gap between what it should carry and what it does

Botanical identity confirmed to Caulophyllum thalictroides by macroscopic, microscopic or DNA methods, distinguishing it from C. giganteum. Quantified N-methylcytisine. Quantified anagyrine with a stated limit. Total saponin content by HPLC with evaporative light scattering detection. Heavy metals and pesticide screens, which matter more than usual because the root is frequently wild-harvested from forest soils.

The wild-harvest problem

United Plant Savers lists blue cohosh on its At-Risk list with an overall at-risk score of 45, and it is threatened in Rhode Island. Seeds may take up to three seasons to germinate, so harvested populations recover slowly. Many labels advertise "wildcrafted" or "ethically wild harvested" material, which means the root came from an uncontrolled forest population with no agronomic record and no way to trace what set its alkaloid content.

What I found in the labels themselves

I pulled the NIH Dietary Supplement Label Database in September 2026. It holds 115 label records containing blue cohosh, of which 79 are on market. I read the full statement text of 78 of those 79. Twenty-seven carry an explicit prohibition against use in pregnancy. Twenty-six mention pregnancy only in a consult-your-provider form. Twenty-five say nothing about pregnancy at all. For the ingredient whose entire commercial reason for existing is late-pregnancy use, and whose entire serious adverse-event record is fetal, only about a third of on-market labels tell a buyer not to take it while pregnant.

The inconsistencies inside single brands are sharper still. Hawaii Pharm's alcohol-based blue cohosh extract says "Consult a physician before using during pregnancy." Hawaii Pharm's non-alcohol extract, the same root from the same company, says "Not to be used during pregnancy." TerraVita's chocolate, vanilla, strawberry and mint glycerites carry no pregnancy language whatsoever. Blue cohosh also appears in products where its presence is hard to justify at all: Totally Products Hearing Support, Nutri-West Core Level Lung and Core Level Pepsin, and several Earth Friend Herb Co. formulas sold for memory, mood and cortisol.

Adverse event surveillance is effectively blind here

FDA's CAERS database, through the July 7, 2026 data release, returns exactly one report matching a blue cohosh product name, and that report is for Gentle Birth Without Blue Cohosh and Red Raspberry, a formula that does not contain it. Zero reports name a blue-cohosh-containing product. That is not evidence of safety. It is evidence that the reporting system cannot see this ingredient, because the buyer is not the person who gets hurt and the injury surfaces in a neonatal intensive care unit rather than a consumer complaint.

Special Considerations

The labor-prep formula category

Mountain Meadow Herbs sells Gentle Birth, a ten-botanical tincture containing blue cohosh alongside blessed thistle, red raspberry, false unicorn, partridge berry, ginger, skullcap, motherwort, wild yam and bayberry. Its label instructs use "during the last 5 weeks of pregnancy," at one quarter teaspoon twice daily in week one and three times daily in weeks two through five, and reads "Midwife-approved." The only pregnancy caution on the bottle is: "If you are pregnant, nursing, have a medical condition, or are taking a prescription, consult your health care provider before using this product." That is boilerplate on a product whose own directions specify a five-week course in the third trimester. The same company also sells Gentle Birth (without Blue Cohosh), which tells you it knows there is a market segment that will not take it.

The professional bodies have not closed the loop

The American College of Nurse-Midwives published Clinical Bulletin Number 18, Induction of Labor, in the Journal of Midwifery and Women's Health in 2022, volume 67, pages 140 to 149, and a position statement on implementing labor induction revised in August 2025. Neither carries a recommendation for or a prohibition against blue cohosh, and I could not locate any ACNM statement that names it. The nearest thing to a professional position remains the McFarlin 1999 survey, which found 69 percent of the midwives using these preparations had learned about them from other midwives, 4 percent from research publications and none from their formal education programs, while 64 percent of the 48 nurse-midwifery education programs surveyed nonetheless taught herbal labor stimulation in their curricula. Dugoua's call for a cohort study has gone unanswered in the eighteen years since.

Post-Roe exposure and species confusion

The Harvard toxicology review of 2023 anticipated increased use of herbal abortifacients following restrictions on mifepristone and misoprostol access. Blue cohosh is on that list, legal, cheap and sold with no age or purchase restriction, and it is the one context where the risk lands on the decision-maker. Separately, nearly all favorable research on this genus, including the caulophine cardiomyocyte work in Basic and Clinical Pharmacology and Toxicology in December 2010, volume 107, pages 976 to 981, concerns the Asian C. robustum, not the plant a US buyer takes home.

Research Status & Evidence Quality

Strong Evidence For

Nothing therapeutic. The strongest evidence here is evidence of harm: four published human case reports, three of them neonatal, detailed in section 12.

Moderate Evidence For

The chemistry and in vitro pharmacology are solid. N-methylcytisine is present in all products analyzed and is teratogenic in rat embryo culture. Taspine is highly embryotoxic in the same model. The saponins produce mitochondrial dysfunction in a validated respiration assay. The alkaloid fraction inhibits four major cytochrome P450 enzymes. None of these are contested, and none are benefits.

Emerging / Preliminary Evidence For

Anti-inflammatory and antiarthritic activity in C. robustum, in mice, in a species that is not what is sold here. Cytotoxicity of caulophine and taspine against tumor cell lines. Pharmacology leads, not clinical findings.

Research Limitations

• Zero randomized controlled trials of crude blue cohosh for any indication, in any population, ever.

• Two randomized trials, 133 women total, of homeopathic caulophyllum only, both rated low quality by Cochrane, both showing no effect on any outcome.

• No human pharmacokinetic data, no placental transfer study, no measurement of what reaches a fetus.

• No dose-response data, so no threshold below which the neonatal risk is known to disappear.

• The primary use cannot ethically be randomized now that three neonatal case reports exist, so this gap is permanent.

• Adverse event surveillance cannot catch the harm, because the exposed patient and the injured patient are different people seen by different specialties.

• Saponin content varies more than 100-fold between products, so even a trial result would not generalize to another bottle.

Summary & Key Takeaways

Blue cohosh was official in the United States Pharmacopeia in the nineteenth century, contains a nicotinic receptor agonist present in every product ever analyzed, has never been tested in a randomized trial in its crude form, and is still sold in chocolate flavor. Its traditional use is a five-week course during the third trimester. Its documented harms are a newborn heart attack, a newborn stroke, and a newborn with permanent brain injury.

Bottom Line

Nobody should take blue cohosh during pregnancy, and there is no evidence-supported reason to take it otherwise. The three neonatal cases are old and few, but they are consistent with each other, with the animal pharmacology and with the chemistry, and no counter-evidence has accumulated in the thirty years since the first one. In a category where most safety debates are about theoretical risk, this one is about three specific infants whose case notes are public.

Key Safety Points

• Blue cohosh is not black cohosh. Different family, different chemistry, different risks, and combination products contain both.

• N-methylcytisine has been found in 100 percent of blue cohosh supplements analyzed by FDA scientists. Anagyrine, the teratogen behind crooked calf disease, is in some products and not others, and no label distinguishes them.

• AHPA's Botanical Safety Handbook classifies blue cohosh as safety class 2b, not to be used during pregnancy.

• Of the 78 on-market labels I read in the NIH label database in September 2026, only 27 carry an explicit pregnancy prohibition and 25 do not mention pregnancy at all.

• Saponin content varies more than 100-fold between products, and daily alkaloid intake from label directions ranges from under 1 mg to 75 mg.

• The alkaloid fraction inhibits CYP3A4, 2C19, 2D6 and 1A2 by more than 80 percent at 100 micrograms per mL.

• There is no antidote and no monitoring test. The fetal exposure is invisible until delivery.

Special Note

Every safety conversation in the supplement aisle rests on an assumption so basic that nobody states it: the person who buys the bottle is the person exposed, and if something goes wrong they will feel it and stop. Blue cohosh breaks that assumption. A woman can take the labeled dose, on schedule, for the full five weeks, feel completely well throughout, and deliver a baby in cardiogenic shock. Carry the test to other shelves: before accepting a product's safety record, ask who the exposed party is and whether they can observe the outcome. Where those are different people, the absence of complaints is not a safety signal. It is a measurement failure.